Mineralys Therapeutics, Common Stock Price Prediction
| MLYS Stock | 12.49 0.62 5.22% |
Oversold Vs Overbought
63
Oversold | Overbought |
EPS Estimate Next Quarter (0.86) | EPS Estimate Current Year (3.61) | EPS Estimate Next Year (3.76) | Wall Street Target Price 32.5714 | EPS Estimate Current Quarter (0.83) |
Using Mineralys Therapeutics, hype-based prediction, you can estimate the value of Mineralys Therapeutics, Common from the perspective of Mineralys Therapeutics, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Mineralys Therapeutics, to buy its stock at a price that has no basis in reality. In that case, they are not buying Mineralys because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Mineralys Therapeutics, after-hype prediction price | USD 12.51 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Mineralys |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics, After-Hype Price Prediction Density Analysis
As far as predicting the price of Mineralys Therapeutics, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Mineralys Therapeutics, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Mineralys Therapeutics,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Mineralys Therapeutics, Estimiated After-Hype Price Volatility
In the context of predicting Mineralys Therapeutics,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mineralys Therapeutics,'s historical news coverage. Mineralys Therapeutics,'s after-hype downside and upside margins for the prediction period are 8.71 and 16.31, respectively. We have considered Mineralys Therapeutics,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Mineralys Therapeutics, is not too volatile at this time. Analysis and calculation of next after-hype price of Mineralys Therapeutics, is based on 3 months time horizon.
Mineralys Therapeutics, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Mineralys Therapeutics, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mineralys Therapeutics, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Mineralys Therapeutics,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 3.80 | 0.02 | 0.00 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
12.49 | 12.51 | 0.16 |
|
Mineralys Therapeutics, Hype Timeline
Mineralys Therapeutics, is now traded for 12.49. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of 0.0. Mineralys is anticipated to increase in value after the next headline, with the price projected to jump to 12.51 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 0.16%, whereas the daily expected return is now at 0.11%. The volatility of related hype on Mineralys Therapeutics, is about 57000.0%, with the expected price after the next announcement by competition of 12.49. Net Loss for the year was (71.9 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Mineralys Therapeutics, Basic Forecasting Models to cross-verify your projections.Mineralys Therapeutics, Related Hype Analysis
Having access to credible news sources related to Mineralys Therapeutics,'s direct competition is more important than ever and may enhance your ability to predict Mineralys Therapeutics,'s future price movements. Getting to know how Mineralys Therapeutics,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Mineralys Therapeutics, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.20) | 6.21 | (9.35) | 34.87 | |
| HCWB | HCW Biologics | 0.01 | 5 per month | 7.39 | 0.1 | 22.00 | (13.64) | 352.85 | |
| SCPH | Scpharmaceuticals | (0.1) | 7 per month | 0.00 | (0.20) | 4.30 | (7.09) | 20.70 | |
| MIST | Milestone Pharmaceuticals | (0.01) | 6 per month | 1.60 | 0.1 | 7.19 | (2.11) | 18.66 | |
| MCRB | Seres Therapeutics | (0.06) | 9 per month | 5.68 | (0.02) | 10.00 | (9.78) | 28.84 | |
| LUMO | Lumos Pharma | (0.05) | 6 per month | 2.60 | 0.11 | 6.35 | (5.19) | 26.13 |
Mineralys Therapeutics, Additional Predictive Modules
Most predictive techniques to examine Mineralys price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mineralys using various technical indicators. When you analyze Mineralys charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Mineralys Therapeutics, Predictive Indicators
The successful prediction of Mineralys Therapeutics, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mineralys Therapeutics, Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mineralys Therapeutics, based on analysis of Mineralys Therapeutics, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mineralys Therapeutics,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mineralys Therapeutics,'s related companies. | 2023 | 2024 (projected) | Current Ratio | 23.76 | 24.95 | Net Debt To EBITDA | 0.58 | 0.55 |
Story Coverage note for Mineralys Therapeutics,
The number of cover stories for Mineralys Therapeutics, depends on current market conditions and Mineralys Therapeutics,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Mineralys Therapeutics, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Mineralys Therapeutics,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Mineralys Therapeutics, Short Properties
Mineralys Therapeutics,'s future price predictability will typically decrease when Mineralys Therapeutics,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Mineralys Therapeutics, Common often depends not only on the future outlook of the potential Mineralys Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mineralys Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.2 M | |
| Cash And Short Term Investments | 236.6 M | |
| Shares Float | 23.9 M |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.